Document is current

Any future updates will be listed below

Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): a multicenter, randomized, phase II trial and biomarker analysis

Crossref DOI link: https://doi.org/10.1038/s41467-026-73562-7

Published Online: 2026-05-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark